Draupnir raises size of PolyPeptide block due to high demand
The majority shareholders of the Swiss pharma chemicals firm sold Sfr171 of shares at the end of the post-IPO lockup
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts